# Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects

> **NCT02084953** · PHASE1 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 59 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** BMS-791325
- **DRUG:** Moxifloxacin
- **DRUG:** Placebo matching BMS-791325

## Key facts

- **NCT ID:** NCT02084953
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2014-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02084953

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02084953, "Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy Subjects". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02084953. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*